Man Group
ONCT

Man Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Man Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-645
Closed -$11K – 2304
2022
Q3 		$11K Buy
+645
New +$13.8K ﹤0.01% 1976

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Man Group's ONCT Position: Q4 2022 in Review

Man Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2022, closing a stake of 645 shares — an estimated $11K sold.

Man Group first reported a position in ONCT in Q3 2022 and held it in 1 quarter. The position peaked at $11K in Q3 2022. 58 funds tracked by Wall St. Rank hold ONCT as of Q4 2022.

  • Man Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Man Group sold 645 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $11K.
  • Man Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Man Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $11K in Q3 2022.
  • 58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.